New Drugs: Faricimab-svoa (Vabysmo ™ ) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti ™ ) for Glaucoma and Ocular Hypertension
The Senior Care Pharmacist · 2023
DOI: 10.4140/tcp.n.2023.497 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Senior Care Pharmacist, 2023. Verfasst von Lana Gettman. Beteiligte Einrichtung: Harding University College of Pharmacy, Searcy, Arkansas. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Glaucoma, Ocular Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo ™ ) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti ™ ) for Glaucoma and Ocular Hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Harding University College of Pharmacy, Searcy, Arkansas.
Zitieren
APA
Gettman, L. (2023). New Drugs: Faricimab-svoa (Vabysmo ™ ) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti ™ ) for Glaucoma and Ocular Hypertension. The Senior Care Pharmacist. https://doi.org/10.4140/tcp.n.2023.497
Vancouver
Gettman L. New Drugs: Faricimab-svoa (Vabysmo ™ ) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti ™ ) for Glaucoma and Ocular Hypertension. The Senior Care Pharmacist. 2023. doi:10.4140/tcp.n.2023.497
BibTeX
@article{Gettman2023,
author = {Gettman, Lana},
title = {New Drugs: Faricimab-svoa (Vabysmo ™ ) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti ™ ) for Glaucoma and Ocular Hypertension},
journal = {The Senior Care Pharmacist},
year = {2023},
doi = {10.4140/tcp.n.2023.497}
}
EUVIMED